Quantcast

Medicago commences U.S. phase I clinical testing of its H1N1 / seasonal vaccine

March 21, 2011

-The Company launches the clinical development of its seasonal flu vaccine-

QUEBEC CITY, March 21 /PRNewswire-FirstCall/ – Medicago Inc. (TSX: MDG) a biotechnology
company focused on developing highly effective and competitive vaccines
based on proprietary manufacturing technologies and Virus-Like
Particles (VLPs), today announced that the first dose of vaccine has
been administered thereby initiating the Company’s phase I H1N1
influenza VLP vaccine candidate (“H1N1 vaccine”) clinical trial in the
United States. The primary safety and immunogenicity results for this
trial are expected within three months.

“We continue to make great strides in the clinical advancement of our
vaccine candidates,” said Andy Sheldon, President and CEO of Medicago.
“With the initiation of this clinical trial, we are in a good position
to report multiple sets of data next quarter including data from this
trial and final phase II data for our pandemic influenza candidate. I
am confident that the quality of data to be obtained from these
clinical trials and our other solid results to date will further
position Medicago as a leader in the development of rapid and
cost-effective vaccines.”

The Phase 1, randomized, double-blind, multicenter, active- and
placebo-controlled dose-ranging study will evaluate the safety,
tolerability and immunogenicity of a single non-adjuvanted dose of the
H1N1 vaccine in 100 healthy adults 18-49 years of age. The subjects
will be randomized to receive one of the following; an injection of the
placebo, Medicago’s H1N1 vaccine or an H1N1 vaccine from a licensed
trivalent vaccine. This phase I trial will lead into Medicago’s U.S.
phase IIa trial for its seasonal trivalent vaccine with the recommended
H1N1, H3N2 and B influenza strains which the Company plans to conduct
later in 2011.

About Seasonal Influenza

Influenza is a contagious respiratory illness that can cause mild to
severe illness, and at times can lead to death. The Centers for Disease
Control and Prevention (“CDC”) states that the best way to prevent
seasonal flu is by getting a seasonal flu vaccination each year.
According to CDC, each year in the United States on average, 5% to 20%
of the population gets the flu; on average, more than 200,000 people
are hospitalized from flu-related complications, and; about 36,000
people die from flu-related causes. Some people, such as elderly
people, young children, and people with certain health conditions, are
at high risk for serious flu complications. According to Datamonitor,
global market projections of seasonal influenza are expected to
increase from $2.8 billion in 2008/2009 to $6.3 billion in 2018/2019.

About Medicago

Medicago is a clinical-stage biotechnology company, developing effective
and competitive vaccines based on proprietary Virus-Like Particles
(VLP) and manufacturing technologies. Medicago is developing VLP
vaccines to protect against pandemic and seasonal influenza, using a
transient expression system which produces recombinant vaccine antigens
in non-transgenic plants. This technology has potential to offer
advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification
and reception of the genetic sequence. This production time frame has
the potential to allow vaccination of the population before the first
wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at www.medicago.com.

Forward Looking Statements

This news release includes certain forward-looking statements that are
based upon current expectations, which involve risks and uncertainties
associated with Medicago’s business and the environment in which the
business operates. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking,
including those identified by the expressions “anticipate”, “believe”,
“plan”, “estimate”, “expect”, “intend”, and similar expressions to the
extent they relate to Medicago or its management. The forward-looking
statements are not historical facts, but reflect Medicago’s current
expectations regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results or events to differ materially from current
expectations, including the matters discussed under “Risks Factors and
Uncertainties” in Medicago’s Annual Information Form filed on March 24,
2010 with the regulatory authorities. Medicago assumes no obligation to
update the forward-looking statements, or to update the reasons why
actual results could differ from those reflected in the forward-looking
statements.

SOURCE Medicago Inc.


Source: newswire



comments powered by Disqus